Gaining an understanding that the activation mutation in the kinase domain of the epidermal growth factor receptor (EGFR) was in close correlation with the sensitivity/resistance to tyrosine kinase inhibitor-based drugs (TKIs) was achieved via studies conducted using lung cancer cell lines [32]. Here, EGFR is linked to lung carcinoma.